CGH
CORT icon

Crossmark Global Holdings’s Corcept Therapeutics CORT Stock Holding History

Crossmark Global Holdings’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$221K Buy
+2,545
New +$154K ﹤0.01% 1193
2021
Q4 		– Sell
-32,910
Closed -$648K – 1392
2021
Q3 		$648K Sell
32,910
-150
-0.5% -$3.14K 0.02% 792
2021
Q2 		$727K Buy
33,060
+180
+0.5% +$4.01K 0.02% 727
2021
Q1 		$782K Buy
32,880
+170
+0.5% +$4.54K 0.02% 685
2020
Q4 		$856K Buy
32,710
+10,274
+46% +$216K 0.02% 613
2020
Q3 		$390K Buy
22,436
+436
+2% +$6.95K 0.01% 886
2020
Q2 		$370K Buy
22,000
+1,700
+8% +$23.9K 0.01% 895
2020
Q1 		$241K Hold
20,300
– – 0.01% 964
2019
Q4 		$246K Buy
20,300
+870
+4% +$12.1K 0.01% 1233
2019
Q3 		$275K Buy
19,430
+190
+1% +$2.33K 0.01% 1101
2019
Q2 		$215K Sell
19,240
-870
-4% -$9.69K 0.01% 1267
2019
Q1 		$236K Sell
20,110
-110
-0.5% -$1.37K 0.01% 1242
2018
Q4 		$270K Sell
20,220
-14,610
-42% -$193K 0.01% 1138
2018
Q3 		$488K Buy
34,830
+450
+1% +$6.29K 0.01% 967
2018
Q2 		$540K Buy
34,380
+2,070
+6% +$36K 0.01% 895
2018
Q1 		$531K Buy
+32,310
New +$599K 0.01% 882

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Crossmark Global Holdings's CORT Position: Q2 2026 in Review

Crossmark Global Holdings opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 2,545 shares worth $221K. The stake represents ﹤0.01% of the portfolio and ranks #1193 among its holdings. This is a return to the name: Crossmark Global Holdings previously reported a position in CORT as recently as Q3 2021.

Crossmark Global Holdings first reported a position in CORT in Q1 2018 and has held it in 16 quarters since. The position peaked at $856K in Q4 2020. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Crossmark Global Holdings held 2,545 shares of Corcept Therapeutics worth $221K as of Q2 2026.
  • Corcept Therapeutics was a new Crossmark Global Holdings position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Crossmark Global Holdings's portfolio in Q2 2026, its #1193 holding.
  • Crossmark Global Holdings first reported a position in Corcept Therapeutics in Q1 2018 and has held it in 16 quarters since.
  • Crossmark Global Holdings's Corcept Therapeutics position peaked at $856K in Q4 2020.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.